Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as an intravenous solution for intravenous use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and metastatic breast cancer, in adult patients who require systemic chemotherapy.

GNH USA supplies Navirel as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to EU quality standards and provides reliable logistics for hospitals, pharmacies and procurement teams across multiple regions, ensuring timely delivery and regulatory compliance.

Vinorelbine is a Vinca alkaloid used in the management of solid tumours by disrupting microtubule formation.

Non‑small cell lung cancer: improves disease control and overall survival in eligible adult patients. Metastatic breast cancer: provides tumor response and disease stabilization in advanced disease. Combination therapy for NSCLC: used with cisplatin to enhance cytotoxic efficacy in first‑line regimens.

Vinorelbine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count leading to infection risk. - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Fatigue: persistent tiredness affecting daily activities. - Alopecia: hair loss that may be temporary or reversible.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection: life‑threatening immune suppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis requiring medical intervention. - Anaphylactic reactions: acute hypersensitivity that may need emergency treatment.

When using Vinorelbine, clinicians should observe specific precautions to minimise risks and optimise patient safety. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess hepatic function: evaluate liver enzymes before and during therapy as metabolism is hepatic. - Evaluate for hypersensitivity: watch for signs of allergic reaction during infusion. - Use caution in neuropathy: patients with pre‑existing peripheral neuropathy may experience worsening symptoms. - Avoid concurrent strong CYP3A4 inhibitors: drugs such as ketoconazole can increase vinorelbine exposure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine interacts with several medicines; understanding the level of interaction guides clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise vinorelbine plasma levels and toxicity. - Concurrent myelosuppressive agents (e.g., cyclophosphamide): increase risk of severe bone‑marrow suppression. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may lower vinorelbine exposure, reducing efficacy. - Anticoagulants (e.g., warfarin): vinorelbine can affect coagulation parameters, requiring INR monitoring. - Other vinca alkaloids (e.g., vincristine): additive neurotoxicity risk warrants dose adjustment.